Citations

Showing 10 of 108119 citations.

Catheter ablation for treatment of atrial fibrillation in patients with heart failure with reduced ejection fraction: A systematic review and meta‐analysis
Agasthi, Pradyumna , Lee, Justin Z. , Amin, Mustapha, Al‐Saffar, Farah , Goel, Vasudha , Almader‐Douglas, Diana , Killu, Ammar M. , Deshmukh, Abhishek , Munoz, Freddy Del‐Carpio , Mulpuru, Siva K. , Tseng, Andrew , Almader-Douglas, Diana, Del-Carpio Munoz, Freddy , Mulpuru, Siva K , Tseng, Andrew S.

Mayo Clinic

Journal of Arrhythmia | January 17, 2019 | Volume: 35 | Issue: 2 | Pages: 171-181

10.1002/joa3.12146 | PMID 31007780 Get It

AbstractBackgroundAtrial fibrillation (AF) among patients with heart failure with reduced ejection fraction (HFrEF) is associated with adverse clinical outcomes. Our primary aim was to evaluate patient‐centered outcomes and surrogate outcomes following catheter ablation (CA) of AF among patients with HFrEF compared to standard medical therapy with or without device therapy (atrioventricular node ablation and cardiac resynchronization therapy).MethodsA systematic literature review was performed limiting our searches to randomized control trials reporting outcomes of CA compared to standard medical therapy with or without device therapy were included. Patient‐centered outcomes were relative reduction in all‐cause mortality, heart failure readmissions, and recurrence of AF. Surrogate outcomes of interest were change in ejection fraction, change in peak oxygen consumption, reduction in brain natriuretic peptide levels, change in 6‐minute walk distance, and change in Minnesota living with heart failure score.ResultsSeven randomized control trials (Patient n = 721) met our inclusion criteria. All trials used radiofrequency energy for CA of AF. CA for AF was associated with significantly lower all‐cause mortality (Risk ratio [RR] = 0.52, 95% confidence interval [CI] = 0.35‐0.76, P = 0.001, I2 = 0%), lower rate of heart failure readmission (RR = 0.58, 95% CI = 0.46‐0.74, P < 0.001, I2 = 0%) and lower rate of AF recurrence (RR = 0.33, 95% CI = 0.22‐0.50, P < 0.001, I2 = 68%) as compared to standard medical therapy. Surrogate outcomes showed a similar benefit favoring CA.Conclusion and RelevanceCatheter ablation for AF in HFrEF is associated with improvement in patient‐centered outcomes and surrogate outcomes when compared to standard medical therapy with or without device therapy.
Development of best practice recommendations for the safe use of pulmonary hypertension pharmacotherapies using a modified Delphi method
Smith, Zachary , Rangarajan, Krishna, Barrow, Jennifer , Carter, Danielle, Falvey, Jennifer , Fester, Keith A. , Guido, M. , Hao, Diana, Ou, Narith N., Pogue, Kristen , MacDonald, Nancy, Barrow, Jennifer, Coons, James C , Dzierba, Amy L. , Guido, Maria R

Mayo Clinic

American Journal of Health-System Pharmacy | January 17, 2019 | Volume: 76 | Issue: 3 | Pages: 153-165

10.1093/ajhp/zxy020 | PMID 30689746 Get It

The β-Adrenergic Agonist Albuterol Improves Pulmonary Vascular Reserve in Heart Failure With Preserved Ejection Fraction
Reddy, Yogesh N.V. , Obokata, Masaru , Koepp, Katlyn E. , Egbe, Alexander C. , Wiley, Brandon M. , Borlaug, Barry A. , Wiley, Brandon, Nishimura, Rick , Borlaug, Barry A , Obokata, Masaru

Mayo Clinic

Circulation Research | January 17, 2019 | Volume: 124 | Issue: 2 | Pages: 306-314

10.1161/circresaha.118.313832 | PMID 30582447 Get It

Rationale: Pulmonary vascular resistance fails to decrease appropriately during exercise in patients with heart failure with preserved ejection fraction (HFpEF). Interventions that enhance pulmonary vasodilation might be beneficial in this cohort but could also worsen left atrial hypertension, exacerbating lung congestion. Intravenous β-agonists reduce pulmonary vascular resistance but are not suitable for chronic use. Objective: We hypothesized that the inhaled β-adrenergic agonist albuterol would improve pulmonary vasodilation during exercise in patients with HFpEF, without increasing left heart filling pressures. Methods and Results: We performed a randomized, double-blind, placebo-controlled trial testing the effects of inhaled albuterol on resting and exercise hemodynamics in subjects with HFpEF using high-fidelity micromanometer catheters and expired gas analysis. The primary end point was pulmonary vascular resistance during exercise. Subjects with HFpEF (n=30) underwent resting and exercise hemodynamic assessment and were then randomized 1:1 to inhaled, nebulized albuterol or placebo. Rest and exercise hemodynamic testing was then repeated. Albuterol improved the primary end point of exercise pulmonary vascular resistance as compared with placebo (−0.6±0.5 versus +0.1±0.7 WU; P =0.003). Albuterol enhanced cardiac output reserve and right ventricular pulmonary artery coupling, reduced right atrial and pulmonary artery pressures, improved pulmonary artery compliance, and enhanced left ventricular transmural distending pressure (all P <0.01), with no increase in pulmonary capillary hydrostatic pressures. Conclusions: Albuterol improves pulmonary vascular reserve in patients with HFpEF without worsening left heart congestion. Further study is warranted to evaluate the chronic efficacy of β-agonists in HFpEF and other forms of pulmonary hypertension. Clinical Trial Registration: URL: http://www.clinicaltrials.gov . Unique identifier: NCT02885636.
Level of block: atrioventricular node, infra-Hisian, or intramyocardial?—Authors’ reply
Padmanabhan, Deepak , Naksuk, Niyada , Kancharla, Krishna , Mulpuru, Siva K. , Mulpuru, Siva

Mayo Clinic

EP Europace | January 17, 2019 | Volume: 21 | Issue: 4 | Pages: 682-682

10.1093/europace/euy319 | PMID 30796457 Get It

Association of mindfulness and stress with menopausal symptoms in midlife women
Sood, Richa , Kuhle, Carol L. , Kapoor, Ekta , Thielen, Jacqueline M., Frohmader, Karla S., Mara, Kristin C. , Mara, Kristin C , Faubion, Stephanie S.

Mayo Clinic

Climacteric | January 17, 2019 | Volume: 22 | Issue: 4 | Pages: 377-382

10.1080/13697137.2018.1551344 | PMID 30652511 Get It

Risk of Parkinson's disease dementia related to level I MDS PD‐MCI
Hoogland, Jeroen , Boel, Judith A., Bie, Rob M.A. de , Schmand, Ben , Geskus, Ronald B. , Dalrymple‐Alford, John C. , Adler, Charles H. , Junqué, Carme , Pedersen, Kenn Freddy , Mollenhauer, Brit , Goldman, Jennifer G. , Tröster, Alexander I. , Burn, David J. , Geurtsen, Gert J. , Disease”, on behalf of the MDS Study Group “Validation of Mild Cognitive Impairment in Parkinson, Adler, C H , Goldman, Jennifer G , Dalrymple-Alford, John C , de Bie, Rob M A , Geurtsen, Gert J , Junque, Carme , Marras, Connie , Weintraub, Daniel , Litvan, Irene , Disease”, on behalf of the MDS Study Group “Validation of Mild Cognitive Impairment in Parkinson

Mayo Clinic

Movement Disorders | January 17, 2019 | Volume: 34 | Issue: 3 | Pages: 430-435

10.1002/mds.27617 | PMID 30653248 Get It

AbstractBackgroundThe International Parkinson and Movement Disorders Society criteria for mild cognitive impairment in PD need validation. The objectives of this present study were to evaluate prognostic validity of level I (abbreviated) International Parkinson and Movement Disorders Society mild cognitive impairment in PD criteria for development of PD dementia and compared them with level II (comprehensive) criteria.MethodsWe analyzed data from 8 international studies (1045 patients) from our consortium that included baseline data on demographics, motor signs, depression, detailed neuropsychological testing, and longitudinal follow‐up for conversion to Parkinson's disease dementia. Survival analysis evaluated their contribution to the hazard of Parkinson's disease dementia.ResultsLevel I mild cognitive impairment in PD, increasing age, male sex, and severity of PD motor signs independently increased the hazard of Parkinson's disease dementia. Level I and level II mild cognitive impairment in PD classification had similar discriminative ability with respect to the time to Parkinson's disease dementia.ConclusionsLevel I mild cognitive impairment in PD classification independently contributes to the hazard of Parkinson's disease dementia. This finding supports the prognostic validity of the abbreviated mild cognitive impairment in PD criteria. © 2019 International Parkinson and Movement Disorder Society
Preparing Regenerative Therapies for Clinical Application: Proposals for Responsible Translation
Smith, Cambray , Arthurs, Jennifer R. , Master, Zubin , Smith, Cambray G, Master, Zubin , Shapiro, Shane A.

Mayo Clinic

Regenerative Medicine | January 17, 2019 | Volume: 14 | Issue: 2 | Pages: 77-84

10.2217/rme-2018-0163 | PMID 30651044 Get It

Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis
Solomon, Scott D. , Adams, David , Kristen, Arnt V. , Grogan, Martha , Maurer, Mathew S. , Merlini, Giampaolo , Slama, Michel , Brannagan, Thomas H., Shah, Amil M. , Garg, Pushkal, Vaishnaw, Akshay, Karsten, Verena, Gollob, Jared , Vest, John, Merlini, Giampaolo , Brannagan, T H , Adams, David , Shah, Amil , Solomon, Scott David , González-Duarte, Alejandra , Maurer, Mathew S , Damy, Thibaud , Dispenzieri, Angela , Berk, John L. , Chen, Jihong , Vest, John, Suhr, Ole B.

Mayo Clinic

Circulation | January 17, 2019 | Volume: 139 | Issue: 4 | Pages: 431-443

10.1161/circulationaha.118.035831 | PMID 30586695 Get It

Background: Hereditary transthyretin-mediated (hATTR) amyloidosis is a rapidly progressive, multisystem disease that presents with cardiomyopathy or polyneuropathy. The APOLLO study assessed the efficacy and tolerability of patisiran in patients with hATTR amyloidosis. The effects of patisiran on cardiac structure and function in a prespecified subpopulation of patients with evidence of cardiac amyloid involvement at baseline were assessed. Methods: APOLLO was an international, randomized, double-blind, placebo-controlled phase 3 trial in patients with hATTR amyloidosis. Patients were randomized 2:1 to receive 0.3 mg/kg patisiran or placebo via intravenous infusion once every 3 weeks for 18 months. The prespecified cardiac subpopulation comprised patients with a baseline left ventricular wall thickness ≥13 mm and no history of hypertension or aortic valve disease. Prespecified exploratory cardiac end points included mean left ventricular wall thickness, global longitudinal strain, and N -terminal prohormone of brain natriuretic peptide. Cardiac parameters in the overall APOLLO patient population were also evaluated. A composite end point of cardiac hospitalizations and all-cause mortality was assessed in a post hoc analysis. Results: In the cardiac subpopulation (n=126; 56% of total population), patisiran reduced mean left ventricular wall thickness (least-squares mean difference ± SEM: –0.9±0.4 mm, P =0.017), interventricular septal wall thickness, posterior wall thickness, and relative wall thickness at month 18 compared with placebo. Patisiran also led to increased end-diastolic volume (8.3±3.9 mL, P =0.036), decreased global longitudinal strain (–1.4±0.6%, P =0.015), and increased cardiac output (0.38±0.19 L/min, P =0.044) compared with placebo at month 18. Patisiran lowered N -terminal prohormone of brain natriuretic peptide at 9 and 18 months (at 18 months, ratio of fold-change patisiran/placebo 0.45, P <0.001). A consistent effect on N -terminal prohormone of brain natriuretic peptide at 18 months was observed in the overall APOLLO patient population (n=225). Median follow-up duration was 18.7 months. The exposure-adjusted rates of cardiac hospitalizations and all-cause death were 18.7 and 10.1 per 100 patient-years in the placebo and patisiran groups, respectively (Andersen–Gill hazard ratio, 0.54; 95% CI, 0.28–1.01). Conclusions: Patisiran decreased mean left ventricular wall thickness, global longitudinal strain, N -terminal prohormone of brain natriuretic peptide, and adverse cardiac outcomes compared with placebo at month 18, suggesting that patisiran may halt or reverse the progression of the cardiac manifestations of hATTR amyloidosis. Clinical Trial Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT01960348.
Item nonresponse on the Myeloproliferative Neoplasms Symptom Assessment Form (MPN-SAF): a comparison of missing data strategies
Mazza, Gina L. , Langlais, Blake, DeWees, T.A. , Geyer, Holly L. , Scherber, Robyn M. , Dueck, Amylou C. , Kunze, Katie L. , Langlais, Blake T., DeWees, Todd A, Dueck, A. C. , DeWees, Todd A , Mazza, Gina L , Kosiorek, Heidi , Mesa, Ruben A.

Mayo Clinic

Leukemia & Lymphoma | January 17, 2019 | Volume: 60 | Issue: 7 | Pages: 1789-1795

10.1080/10428194.2018.1548705 | PMID 30652523 Get It

Outcomes of hospitalizations with atrial fibrillation-flutter on a weekday versus weekend: an analysis from a 2014 nationwide inpatient sample
Voruganti, Dinesh , Deshmukh, Abhishek , Shantha, Ghanshyam , GIUDICI, MICHAEL C.

Mayo Clinic

PeerJ | January 17, 2019 | Volume: 7 | Issue: No issue available | Pages: e6211

10.7717/peerj.6211 | PMID 30671298 Get It

Background Patients with atrial fibrillation-flutter (AF) admitted on the weekends were initially reported to have poor outcomes. The primary purpose of this study is to re-evaluate the outcomes for weekend versus weekday AF hospitalization using the 2014 Nationwide Inpatient Sample (NIS). Methods Included hospitalizations were aged above 18 years. The hospitalizations with AF were identified using the international classification of diseases 9 (ICD-9) codes (427.31, 427.32). In-hospital mortality, length of stay (LOS), other co-morbidities, cardioversion procedures, and time to cardioversion were recorded. All analysis was performed using SAS 9.4 statistical software (Cary, North Carolina). Results A total of 453,505 hospitalizations with atrial fibrillation and flutter as primary discharge diagnosis were identified. Among the total hospitalizations with a primary diagnosis of AF, 20.3% were admitted on the weekend. Among the weekend hospitalizations, 0.19% died in hospital compared to 0.74% among those admitted during the week. After adjusting for patient characteristics, hospital characteristics and disease severity, the adjusted odds for in-hospital mortality were not significantly different for weekend vs. weekday hospitalizations (OR = 0.91, 95% CI [0.77–1.11]; p = 0.33). The weekend admissions were associated with significantly lower odds of cardioversion procedures (OR = 0.72, 95% CI [0.69–0.76], P < 0.0001), lower cost of hospitalization (USD 8265.8 on weekends vs. USD 8966.5 on the weekdays, P < 0.001), slightly lower rate of anticoagulation (17.09% on the weekends vs. 18.73% on the weekdays. P < 0.0001), and slightly increased time to cardioversion (1.94 days on the weekend vs. 1.73 days on weekdays, P < 0.0005). The mean length of hospital stay (LOS) was statistically not different in both groups: (3.49 days ± 3.70 (SD) in the weekend group vs. 3.47 days ± 3.50 (SD) in the weekday group, P = 0.42) Discussion The weekend AF hospitalizations did not have a clinically significant difference in mortality and LOS compared to those admitted on a weekday. However, the use of cardioversion procedures and cost of hospitalization was significantly lower on the weekends.